Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by Kaplan Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Kaplan Medical Center Identifier:
First received: April 26, 2007
Last updated: June 5, 2007
Last verified: May 2007

A Prospective Double Blind RCT: Controlled Release Oxycodone 10 mg On a 12 h Dosing Schedule Started With The Premedication ,Placebo Controlled Study,On Post Operative Analgesia Management in Laparoscopic Cholecystectomy and Laparoscopic Bilateral Inguinal Hernia (BIH).

CRO is indicated for the management of moderate to severe pain when a continuous,around the clock analgesic is needed for an extended period of time.Its safety and efficacy in the first 12-24 hours post operative has not been established.

Condition Intervention Phase
Elective Laproscopic Bilateral Inguinal Hernia
Elective Laproscopic Cholecystectomy
Drug: Oxycodone 10 mg
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy : Prospective Double Blind, Randomized, Placebo-Controlled Study

Resource links provided by NLM:

Further study details as provided by Kaplan Medical Center:

Estimated Enrollment: 100
Study Start Date: July 2007
Estimated Study Completion Date: July 2008

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Local ethic committee approval
  • Written informed consent
  • ASA physical status I-III, scheduled for elective laparoscopic cholecystectomy and elective laparoscopic BIH

Exclusion Criteria:

  • Difficulty in communication
  • Allergy to oxycodone and/or morphine
  • Allergy to local anesthetic
  • History of alcohol and substance abuse
  • Treated depression
  • Chronic use of opioid or tramadol or NSAIDS
  • Pregnancy
  • Obstructive sleep apnea
  • Anticipated fiber optic intubation
  • Severe hepatic or renal impairment
  • Weight <50 kg or > 100 kg
  • Conversion to laparotomy
  • Patient extubated in PACU.
  • Any prior abdominal surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00480142

Contact: Oscar Liphshitz, MD 0524782736

Sponsors and Collaborators
Kaplan Medical Center
Principal Investigator: patricia grosman, MD Israel: Kaplan Hospital, Clalit Health Service
Study Chair: Eli Mavor, MD Israel:Clalit Health Service
Study Director: oscar liphshitz, MD Isreal: Kaplan: Clalit Health Service
Study Director: Bella Almog, R.N MA Israel: Kaplan: Clalit Health Service
  More Information Identifier: NCT00480142     History of Changes
Other Study ID Numbers: kmc070012CTIL
Study First Received: April 26, 2007
Last Updated: June 5, 2007

Additional relevant MeSH terms:
Hernia, Inguinal
Pathological Conditions, Anatomical
Hernia, Abdominal
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on May 24, 2017